Skip to content

Study on the effect of low concentrations of atropine on ocular surface and meibomian glands in children

Study on the effect of low concentrations of atropine on ocular surface and meibomian glands in children

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077046
Enrollment
Unknown
Registered
2023-10-27
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eyes

Interventions

0.01% concentration atropine group:Use 0.01% concentration atropine drops for both eyes nightly, one drop once a day
0.02% concentration atropine group:Use 0.02% concentration atropine drops for both eyes nightly, one drop once a day
Blank control group:Do not use any eye drops

Sponsors

The Second Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1) Sign the informed consent form and be willing to follow up according to the prescribed time; 2) Age 6~10 years old, gender and race are not limited; 3) Normal near vision, distance vision < 1.0, distance vision can be corrected with concave lens (corrected visual acuity is = 1.0); 4) -0.5D= diopter =-6.00D, astigmatism=0.75DC; 5) Can adhere to medication for 12 months; 6) Only wear monofocal glasses to control myopia.

Exclusion criteria

Exclusion criteria: 1) History of systemic diseases related to ocular surface diseases, such as rheumatoid arthritis, gout and other rheumatological immunology diseases, thyroid diseases, diabetes mellitus; 2) Eyelid and skin inflammation, such as anterior blepharitis, atopic dermatitis, seborrheic dermatitis, rosacea, etc.; 3) Eyelid and conjunctival scarring lesions, such as trachoma, pemphigoid, chemical injury, thermal burn, radiation injury, etc.; 4) Ocular drug history: drugs that affect tear secretion and tear film stability, such as artificial tears, corticosteroid drugs, non-steroidal anti-inflammatory drugs, etc.; 5) History of previous ophthalmic surgery, eye trauma, and eye burns.

Design outcomes

Primary

MeasureTime frame
Tear River height;Tear film breakup time;Degree of meibomian gland deletion and glandular morphological changes;OSDI questionnaire;

Secondary

MeasureTime frame
Lipid layer thickness grading;Conjunctival congestion score;Corneal fluorescence staining score;

Countries

China

Contacts

Public ContactJing Wang

The Second Affiliated Hospital of Anhui Medical University

15056967187@163.com+86 150 5696 7187

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026